THE INFLUENCE OF HYPERPROLACТINEMIA ON THE LEVEL OF FSH AND LH IN WOMEN

Prolactin as a hormone secreted by lactotrophs of the adenocyphosis primarily affects lactation in mammals, that is, on the production of milk (lactogenesis), the development and branching of the milk channels (mamogenesis) and the removal of milk through the nipples (galactopoezis). Other significant biological effects of prolactin include maintaining the internal homeostasis of the organism acting as an osmoregulatory hormone, as an luteotrophic hormone and has an immunological role in the body. Excretion of prolactin is regulated by the action of prolactin stimulating and prolactin inhibiting factors of the hypothalamus. By maintaining a balance in the excretion of these factors, the level of concentration of prolactin in the serum is in normal reference values. Disturbance in the excretion of dopamine as the strongest prolactin secretion inhibitor increases the level of prolactin, a condition known as hyperprolactinaemia, in which all hormones important for the normal menstrual cycle are inhibited, leading to reduced production of ovarian follicles and ovarian steroids, anovulation and sterility in women. The purpose of this study was to determine the level of prolactin in a group of patients with established hyperprolactinaemia in relation to the control group of patients and determining the level of gonadotrophic hormones FSH and LH in hyperprolactinemic patients in relation to the control group. The aim was also to see the effect of Bromergon or Dostinex in hyperprolactinemic patients on the level of FSH and LH after receiving the therapy. Patients aged 25 to 35 years with pre-diagnosed hyperprolactinaemia were examined. Prolactin, FSH and LH were examined from the parameters. Patients were divided into three groups, a control group of patients, a group of patients with diagnosed hyperprolactinaemia, and a group of patients treated with Bromergon or Dostinex. From the results obtained, it became clear that in the control group of patients, the levels of prolactin, FSH and LH were in normal reference values. In the hyperprolactinemic patients, prolactin has been significantly increased, but after the dose of Dostinex or Bromergon in the treated group, the level of prolactin significantly decreases to values close to the control group. It was noted that the concentration of FSH in hyperprolactinemic patients was lower in relation to the concentration of FSH in the control group, and the serum FSH level in patients treated with antiprolactin therapy was increased to a level higher than the concentration of FSH in the control group.The level of LH in the serum from hyperprolactinemic patients is less than LH level in the control group, but to a lesser extent compared to the level of FSH under the same conditions. In the treatment of patients with antiprolactin therapy there is an increase in serum concentrations of LH with values significantly higher than the control group.